Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
Public ClinicalTrials.gov record NCT05114486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of the Safety and Efficacy of 2% Pilocarpine Ophthalmic Spray Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting study inclusion/exclusion criteria are scheduled for 2 treatment visits. At each treatment visit, 1 of the 2 study treatments is self-administered to both eyes. Afterwards, efficacy and safety assessments are performed over a 3-hour period.
Study identification
- NCT ID
- NCT05114486
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- Pilocarpine Ophthalmic administered with the Optejet dispenser Combination Product
- Placebo administered with the Optejet dispenser Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 40 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2021 (Actual)
- Primary completion
- Sep 20, 2022 (Actual)
- Completion
- Sep 20, 2022 (Actual)
- Last update posted
- Sep 11, 2023
2021 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VISION-2 Study Site #57 | San Diego | California | 92131 | — |
| VISION-2 Study Site #59 | Fairfield | Connecticut | 06890 | — |
| VISION-2 Study Site #56 | Louisville | Kentucky | 40206 | — |
| VISION-2 Study Site #19 | Columbus | Ohio | 43210 | — |
| VISION-2 Study Site #58 | Philadelphia | Pennsylvania | 19141 | — |
| VISION-2 Study Site #62 | Sioux Falls | South Dakota | 57018 | — |
| VISION-2 Study Site #55 | Memphis | Tennessee | 38119 | — |
| VISON-2 Study Site #60 | Austin | Texas | 78731 | — |
| VISION-2 Study Site #61 | Draper | Utah | 84020 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05114486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05114486 live on ClinicalTrials.gov.